Coverage
-
December 16, 2023
The Fifth Circuit on Friday vacated the Federal Trade Commission's order blocking Illumina's $8 billion reacquisition of cancer-detection company Grail, agreeing with the commission that the combination is "likely to substantially lessen competition," but finding that the FTC used the wrong legal standard in part of its analysis.
17 other articles on this case.
View all »